Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer

American Journal of Cancer Research

Volumn 5, Issue 4, 2015, Pages 1519-1530

  Ye, Qin ^a,b   Holowatyj, Andreana ^a   Wu, Jack ^a   Liu, Hui ^a   Zhang, Lihong ^a,c   Suzuki, Takayoshi ^d   Yang, Zeng Quan ^a,e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JIANGSU NORMAL UNIVERSITY   (China)

^c Shandong Provincial Key Laboratory for Improving Birth Outcome Technique   (China)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; GASC1; Gene amplification; Histone demethylase; KDM4

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE DEMETHYLASE; HISTONE LYSINE DEMETHYLASE KDM4; HISTONE LYSINE DEMETHYLASE KDM4A; HISTONE LYSINE DEMETHYLASE KDM4B; HISTONE LYSINE DEMETHYLASE KDM4C; HISTONE LYSINE DEMETHYLASE KDM4D; MESSENGER RNA; NCDM 32B; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; PHENOTYPE; PROTEIN EXPRESSION; UPREGULATION;

EID: 85006226811     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS and Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
2. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics 2012; 6: 289-297.
3. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
4. Kooistra SM and Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012; 13: 297-311.
5. Greer EL and Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13: 343-357.
6. Labbe RM, Holowatyj A and Yang ZQ. Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential. Am J Transl Res 2014; 6: 1-15.
7. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
8. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH and Helin K. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006; 442: 307-311.
9. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M and Shi Y. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 2006; 125: 467-481.
10. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I and Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837.
11. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ and Zhao K. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40: 897-903.
12. Hillringhaus L, Yue WW, Rose NR, Ng SS, Gileadi C, Loenarz C, Bello SH, Bray JE, Scho-field CJ and Oppermann U. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family. J Biol Chem 2011; 286: 41616-41625.
13. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Can-cer Discov 2012; 2: 401-404.
14. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, Mack S, Kongkham PN, Peacock J, Dubuc A, Ra YS, Zilberberg K, McLeod J, Scherer SW, Sunil Rao J, Eberhart CG, Graj-kowska W, Gillespie Y, Lach B, Grundy R, Poll-ack IF, Hamilton RL, Van Meter T, Carlotti CG, Boop F, Bigner D, Gilbertson RJ, Rutka JT and Taylor MD. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009; 41: 465-472.
15. Vinatzer U, Gollinger M, Mullauer L, Raderer M, Chott A and Streubel B. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JM-JD2C, and CNN3. Clin Cancer Res 2008; 14: 6426-6431.
16. Italiano A, Attias R, Aurias A, Perot G, Burel-Vandenbos F, Otto J, Venissac N and Pedeutour F. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet Cytogenet 2006; 167: 122-130.
17. Suikki HE, Kujala PM, Tammela TL, van We-erden WM, Vessella RL and Visakorpi T. Gen-etic alterations and changes in expression of histone demethylases in prostate cancer. Pro-state 2010; 70: 889-898.
18. Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP and Yang ZQ. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 2009; 28: 4491-4500.
19. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Moller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D and Staudt LM. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010; 18: 590-605.
20. Luo W, Chang R, Zhong J, Pandey A and Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A 2012; 109: E3367-3376.
21. Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Imamura M, Sugano S, Nakamura Y and Inazawa J. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 2000; 60: 4735-4739.
22. Berry WL, Shin S, Lightfoot SA and Janknecht R. Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol 2012; 41: 1701-1706.
23. Kawazu M, Saso K, Tong KI, McQuire T, Goto K, Son DO, Wakeham A, Miyagishi M, Mak TW and Okada H. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gl-and development. PLoS One 2011; 6: e17830.
24. Gaughan L, Stockley J, Coffey K, O'Neill D, Jones DL, Wade M, Wright J, Moore M, Tse S, Rogerson L and Robson CN. KDM4B is a Master Regulator of the Estrogen Receptor Signalling Cascade. Nucleic Acids Res 2013; 41: 6892-6904.
25. Yang ZQ, Streicher KL, Ray ME, Abrams J and Ethier SP. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res 2006; 66: 11632-11643.
26. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP and Ethier SP. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 1999; 81: 1328-1334.
27. Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun YC, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signal 2013; 6: pl1.
28. Liu L, Kimball S, Liu H, Holowatyj A and Yang ZQ. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget 2015; 6: 2466-2482.
29. Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M and Perou CM. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 2013; 142: 237-255.
30. Hamada S, Suzuki T, Mino K, Koseki K, Oehme F, Flamme I, Ozasa H, Itoh Y, Ogasawara D, Komaarashi H, Kato A, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T and Miyata N. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. J Med Chem 2010; 53: 5629-5638.
31. Hamada S, Kim TD, Suzuki T, Itoh Y, Tsumoto H, Nakagawa H, Janknecht R and Miyata N. Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors. Bioorg Med Chem Lett 2009; 19: 2852-2855.
32. Suzuki T and Miyata N. Lysine demethylases inhibitors. J Med Chem 2011; 54: 8236-8250.
33. Savelyeva L, Claas A, An H, Weber RG, Lichter P and Schwab M. Retention of polysomy at 9p 23-24 during karyotypic evolution in human breast cancer cell line COLO 824. Genes Chromosomes Cancer 1999; 24: 87-93.
34. Kim TD, Fuchs JR, Schwartz E, Abdelhamid D, Etter J, Berry WL, Li C, Ihnat MA, Li PK and Janknecht R. Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors. Am J Transl Res 2014; 6: 236-247.
35. Kupershmit I, Khoury-Haddad H, Awwad SW, Guttmann-Raviv N and Ayoub N. KDM4C (GASC1) lysine demethylase is associated with mitotic chromatin and regulates chromosome segregation during mitosis. Nucleic Acids Res 2014; 42: 6168-6182.
36. Mallette FA, Mattiroli F, Cui G, Young LC, Hen-dzel MJ, Mer G, Sixma TK and Richard S. RNF8- and RNF168-dependent degradation of KD-M4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J 2012; 31: 1865-1878.
37. Burton A, Azevedo C, Andreassi C, Riccio A and Saiardi A. Inositol pyrophosphates regulate JMJD2C-dependent histone demethylation. Proc Natl Acad Sci U S A 2013; 110: 18970-18975.
38. Das PP, Shao Z, Beyaz S, Apostolou E, Pinello L, De Los Angeles A, O'Brien K, Atsma JM, Fujiwara Y, Nguyen M, Ljuboja D, Guo G, Woo A, Yuan GC, Onder T, Daley G, Hochedlinger K, Kim J and Orkin SH. Distinct and combinatorial functions of Jmjd2b/Kdm4b and Jmjd2c/Kd-m4c in mouse embryonic stem cell identity. Mol Cell 2014; 53: 32-48.
39. Ho-Yen CM, Green AR, Rakha EA, Brentnall AR, Ellis IO, Kermorgant S and Jones JL. C-Met in Invasive Breast Cancer. Cancer 2014; 120: 163-171.
40. Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, Migliardi G, Molyneux G, Perera T, Comoglio PM, Boccaccio C, Smalley MJ, Bertotti A and Trusolino L. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. On-cogene 2013; 32: 1428-1440.